Status:

TERMINATED

Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections

Lead Sponsor:

Menarini Group

Conditions:

Surgical Site Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to assess the efficacy and safety of delafloxacin administered as IV and oral formulation in comparison with Best Available Therapy (BAT) in patients with superficial or d...

Detailed Description

This is a randomized, observer-blinded, active-controlled, parallel-group, multicenter, phase IIIb study for the treatment of incisional, superficial or deep, surgical site infection after cardiothora...

Eligibility Criteria

Inclusion

  • Male or female patients aged more than 18 years.
  • Patients with a history of cardiothoracic / related leg or abdominal surgery, occurred within 30 days and no implant is left in place, and a diagnosis of superficial or deep SSI according to the CDC definition.
  • The severity of infection requires an IV treatment and patient hospitalization according to the Investigator's judgment.

Exclusion

  • Previous IV antimicrobial therapy exceeding 24-hour duration during 72 hours prior to first dose.
  • Any infection expected to require systemic antimicrobial agents other than study treatment(s).
  • Medical history of significant hypersensitivity or allergic reaction or contraindication to the study drugs
  • Medical history of central nervous system (CNS) disorders
  • Medical history of myasthenia gravis.
  • Medical history of C. difficile diarrhea.
  • Organ-space infection.
  • Complicated Intra-Abdominal Infection (cIAI)
  • Chronic or underlying conditions at site of infection that may complicate the assessment of clinical response or would interfere with SSI healing.
  • Underlying disease leading to deep immunosuppressive status.
  • End-stage renal disease, CrCl \<15 mL/min.

Key Trial Info

Start Date :

September 25 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 28 2020

Estimated Enrollment :

268 Patients enrolled

Trial Details

Trial ID

NCT04042077

Start Date

September 25 2019

End Date

October 28 2020

Last Update

February 2 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Agostino Gemelli

Roma, Italy